Whole Body MRI: Improved Lesion Detection and Characterization With Diffusion Weighted Techniques

Rajpaul Attariwala, MD, PhD FRCP FANM,* and Wayne Picker, M. Hlth. Sc. (MRI)

This manuscript underwent peer review in line with the standards of editorial integrity and publication ethics maintained by Journal of Magnetic Resonance Imaging. The peer reviewers have no relevant financial relationships. The peer review process for Journal of Magnetic Resonance Imaging is double-blinded. As such, the identities of the reviewers are not disclosed in line with the standard accepted practices of medical journal peer review.

Conflicts of interest have been identified and resolved in accordance with Blackwell Futura Media Services’s Policy on Activity Disclosure and Conflict of Interest. No relevant financial relationships exist for any individual in control of the content and therefore there were no conflicts to resolve.

INSTRUCTIONS ON RECEIVING CREDIT
For information on applicability and acceptance of CME credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within an hour; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity during the valid credit period.

Follow these steps to earn credit:

- Log on to www.wileyhealthlearning.com
- Read the target audience, educational objectives, and activity disclosures.
- Read the article in print or online format.
- Reflect on the article.
- Access the CME Exam, and choose the best answer to each question.
- Complete the required evaluation component of the activity.

This activity will be available for CME credit for twelve months following its publication date. At that time, it will be reviewed and potentially updated and extended for an additional period.
Diffusion-weighted imaging (DWI) is an established functional imaging technique that interrogates the delicate balance of water movement at the cellular level. Technological advances enable this technique to be applied to whole-body MRI. Theory, b-value selection, common artifacts and target to background for optimized viewing will be reviewed for applications in the neck, chest, abdomen, and pelvis. Whole-body imaging with DWI allows novel applications of MRI to aid in evaluation of conditions such as multiple myeloma, lymphoma, and skeletal metastases, while the quantitative nature of this technique permits evaluation of response to therapy. Persisting signal at high b-values from restricted hypercellular tissue and viscous fluid also permits applications of DWI beyond oncologic imaging. DWI, when used in conjunction with routine imaging, can assist in detecting hemorrhagic degradation products, infection/abscess, and inflammation in colitis, while aiding with discrimination of free fluid and empyema, while limiting the need for intravenous contrast. DWI in conjunction with routine anatomic images provides a platform to improve lesion detection and characterization with findings rivaling other combined anatomic and functional imaging techniques, with the added benefit of no ionizing radiation.

**Key Words:** MRI; whole body MRI; diffusion-weighted imaging DWI; oncology imaging; b-value; apparent diffusion coefficient ADC

*J. Magn. Reson. Imaging* 2013;38:253-268. © 2013 Wiley Periodicals, Inc.

**ONGOING TECHNOLOGICAL AND computer processing advances with MRI have ushered in a new era of whole-body imaging. Using multi-station, or even continuous moving table technology allows complete imaging from the head to foot, with conventional anatomic sequences such as T1, T2, STIR, and angiographic protocols routinely being performed (1-5). These morphologic techniques take advantage of MRI’s exquisite contrast and spatial resolution to provide great detail of the whole-body anatomy and organ specific tissue composition. A relatively new MRI sequence that takes advantage of these recent technological advances is diffusion-weighted imaging (DWI). This functional technique has long been used in the brain to demonstrate alteration in intra- and extracellular water content from disruption of the transmembrane water flux. These cellular level alterations are visible before changes can be identified on morphologic routine sequences. This technique in the brain was first described by LeBihan and Breton (6), and is routinely used in assessment for early ischemia. Application of DWI to the body is more complex secondary to the greater variability of tissue body water composition and due to the complexity imparted from organ movement. Technological advances such as parallel imaging, echo planar imaging, and multichannel receiver coils have enabled these difficulties to be overcome, allowing high-quality repeatable application of DWI to the whole body (7,8).

Whole-body MRI has continually evolved as a detection method for a variety of pathologic processes. In addition to vascular applications, it has been used for detection of unknown primary malignancy, determining skeletal spread of metastasis, and as a cancer screening and staging tool (1,3,9).

**BACKGROUND CONSIDERATIONS FOR CLINICAL WHOLE-BODY DIFFUSION**

DWI with MRI was first described by Stejskal and Tanner (10) and is based on steady-state kinetic Brownian motion of a solute in a solvent. Einstein in 1905 (11) applied this principle to a Stokes particle in quiescent fluid at a uniform temperature, which resulted in the Stokes-Einstein Eq. [1] upon which diffusion weighting imaging is based.

\[
D = \frac{k_b T}{6\pi \eta r}
\]

For body temperature and based on semisolid tissue, \(k_b\) and T are constants, while \(r\) represents a solute molecule subject to viscosity \(\mu\). When applied to the body, \(r\) is on the same order of magnitude as a cell, and thus diffusion represents an effective mean free path of water in both the intracellular and extracellular environment. For the application of diffusion to the body, unlike the central nervous system, water is not as tightly regulated. In the body, water movement is both flow and tissue dependent, and the fat signal needs to be eliminated to have a rapid water selective sequence. Various fat suppression techniques have been used, with nonselective STIR sequences being commonly used at for whole body at 1.5 Tesla (T) (12,13). Areas of incomplete fat saturation commonly occur at edge of field and where the prescan radiofrequency (RF) map is inhomogeneous. These areas are commonly seen at the neck/shoulder interface, at fat/air gaps in the bowel/low pelvis, between the thighs and adjacent to pendulous breast tissue. These areas frequently have restricted signal changes and thus reviewing diffusion images in conjunction with conventional MRI sequences is invaluable. These errors can also be minimized by shortening the z-axis imaged field of view to optimize imaging around isocenter, and by optimizing the receiver bandwidth (13).

DWI with fat background suppression (DWIBS), was first applied to whole-body MRI imaging by Takahara et al (12), and is based on water motion probing gradients. Motion probing gradients are a method of nondirectionally sensitizing water to determine the water movement between diffusion sensitizing gradient pulses (Fig. 1). If water moves substantially between diffusion sensitizing gradients, the resulting bulk water signal would be low; however, if water is restricted from moving between diffusion sensitizing gradients, the signal would be high. The diffusion gradient strength, b-value [s/mm²], was first described by LeBihan in 1985 (6). The b-value is dependent on the duration of the diffusion sensitizing gradient, amplitude, and time between application of the sensitizing gradient. Typically, to increase the b-value, greater amplitude of the diffusion sensitizing gradient is applied (Fig. 2).

The log signal intensity versus b-values for a specific tissue can be obtained, and is frequently
termed the tissue diffusion curve, which essentially serves as a water-based fingerprint of the tissue being examined (14). The simplest diffusion model assumes tissue is homogeneous, and results in a straight monoexponential line of signal intensity versus b-value. However, the body tissue microenvironment at which water diffusion is measured is inhomogeneous (non-Gaussian), due to cellular compartments, membranes, and vascularity, which result in the tissue diffusion curve being nonlinear. The most pronounced nonlinear effects are due to vascular perfusion, predominantly capillary flow (15,16), and occurs in addition to the bulk diffusion (Figs. 3, and 4). Thus a bi-exponential tissue diffusion model obtained by a minimum of three b-values resulting in two logarithmic linear components: one for perfusion/flow effects at b-values from 0 to 100 s/mm² and another for tissue b-values above 100 s/mm² for bulk diffusion, can suffice for most clinical applications of diffusion body imaging. Because of the additive effects of perfusion and bulk diffusion, there is a steepening of the slope of the diffusion curve that occurs at b-values less than 100 s/mm² (Fig. 5). Extrapolating and then subtracting the b<100 s/mm² bulk diffusion component from the diffusion component, a technique known as curve stripping, at b=0 yields the flow or perfusion fraction which compares well with in vivo experimental data (17). Using multiple b-values can yield further refinements to the tissue diffusion curve, and this is typically referred to as intravoxel incoherent motion (IVIM). When the IVIM curve for a tissue is obtained, the bi-exponential data can also readily be extracted. More complex methods such as kurtosis, which assesses the probability extent of non-Gaussian behavior, and diffusion tensor imaging (DTI) have also been applied to body tissue diffusion investigation.

Obtaining multiple high b-values for IVIM curves is time-consuming and error prone because as b-values rise, signal intensity decreases resulting in loss of lesion to background tissue conspicuity. At high b-values, the relative signal intensity error increases because the signal approaches the noise floor level with resultant poor signal to noise ratio. The lack of standardization, phantoms, or calibration factors results in each machine configuration having its own intrinsic signal to noise, and specific noise floor characteristics.

To aid in lesion characterization, functional imaging techniques are commonly applied; wherein the lesion signal behavior is assessed relative to known tissue. Commonly in the body, this has led to assessing the lesion signal to the tightly regulated anisotropic spinal cord signal (18); yielding the lesion to spine ratio. The signal from the spinal cord effectively acts as an intrinsic calibrating factor, which can be used as a qualitative surrogate for assessment of b-value signal to noise.

The apparent diffusion coefficient [ADC] represents the absolute value of the slope of any two points on the diffusion curve and is calculated (Eq. [2]) using the b-values and signal intensity (SI) (Fig. 5).

\[
ADC = \frac{1}{(b_2 - b_1)} \ln \left( \frac{SI(b_1)}{SI(b_2)} \right)
\]  

Most vendors by default use a voxel-based best fit linear monoexponential curve to calculate the ADC, which can lead to considerable error when b-values below 100 s/mm² are used in the calculation, as the effect of perfusion will result in steepening of the best fit curve, and thus an overestimation of the ADC. However, not all vendors allow selection of specific b-values, for ADC and perfusion/flow fraction calculations.

Based on the Stokes-Einstein Eq. [1], the impact of changes in tissue water motion, and solvent viscosity can be predicted, yielding increased signal for solid tissue, or viscous fluid. A generalization of expected slopes and signal intensity for tissue encountered in body imaging is shown in Figure 6. Due to lack of standardization, the difference between signal intensity of a restricted tissue versus normal tissue at a fixed b-value cannot be adequately quantified; however, the relative difference can be used to increase lesion conspicuity. This fact can aid with discriminating empyema versus simple pleural effusion (19,20) and peritoneal carcinomatosis versus ascites (21,22), which are difficult to distinguish by conventional sequences. The persistence of increased signal with
restricted solid tissue corresponds to the lower ADC values described for solid tumor masses. However, the lack of standardization (23) of b-value selection for various organs and lesions limits the reproducibility of ADC values. A generalization of change in ADC values between vascular, cystic, necrotic/viscous, and solid tissue is outlined in Figure 6b. Thus, the low

Figure 3. Diffusion imaging of a cross section through the abdomen at b-values of 0 (a), 200 (b), 800 (c), and 1000(d) s/mm². At a b-value of 0, note the dark areas representing fluid, flowing or static. At a b-value of 200, flowing fluids are no longer visible. As b-values increase, there is a resultant loss of background tissue, with minimal normal background liver seen at b-value of 1000 (d).

Figure 4. Generic body tissue diffusion curve. Log signal intensity versus b-values for most body tissues show a biexponential behavior with an inflection around b-value of 100 s/mm². At b-values below 100 (shaded), there is a tissue-dependent and additive perfusion flow effect resulting in increased signal intensity which can skew ADC calculations. At b-values above 100, the perfusion effects in the body are limited, resulting in an essentially linear true diffusion slope.

Figure 5. Tissue diffusion IVIM curve. The apparent diffusion (ADC) is the absolute value of the slope of the curve. As higher b-values are used, the background signal decreases.
ADC of a solid lesion undergoing therapy can change. Necrotic or edematous tissue will result in an increase in the ADC value. This quantifiable change, if performed at both baseline and following treatment with the same b-values, can be used to monitor response to treatment.

ADC maps are an image-based mathematical displayed calculation that is subject to inherent errors present in its underlying individual b-value image map components. These errors include inhomogeneous fat suppression, high b-value noise floor effects, movement that can lead to misregistration, edge of field effect, or other gradient/echo planar induced artifacts. Thus to minimize these errors, it is prudent to view the raw b-value images directly in conjunction with conventional coregistered sequences. To detect such errors, it is beneficial to obtain sufficient background signal from the organ in question to be able to localize a lesion. Background signal is rapidly lost at high b-values (greater than 800 s/mm$^2$), with large patients, and with inhomogeneous RF maps. Increasing the number of averages to increase signal increases scan time. Near the diaphragm this can magnify errors. Therefore optimal b-value selection should be sought to provide the optimal target to background signal based on machine specific intrinsic resolution.

Misregistration is a common artifact that can occur most commonly at sites of maximum movement (i.e., near diaphragm, where with free-breathing techniques, the b-value maps are not obtained with the organ in question in the exact same position (Fig. 7). This results in ADC map noise, with the risk of loss of detection, or incorrect characterization of a lesion. This potential error can be minimized with diaphragm gating techniques, and stresses the importance of coregistered anatomic routine sequences acquired in conjunction with DWI.

At 3T, the benefit of increased SNR for DWI is offset by an increase in image distortion and artifacts. Field inhomogeneities are compounded, and dielectric effects, incomplete fat saturation and increased eddy currents result in increased DWI signal distortion. These effects can be mitigated by multitransmit RF shimming coils. Rosenkrantz et al (24) have demonstrated no significant difference in ADC values at 1.5T and 3T in matched patients with the same b-values and ADC calculation methods, however, the authors report significantly lower subjective image quality at 3T.

Use of conventional sequences with whole-body imaging at 3T is problematic due to specific absorption rate (SAR) heating effects which are proportional to the square of the static field and the flip angle. Thus the SAR limit is frequently attained at 3T (25). However, the higher SAR requires cooling pauses during scanning (26) which can result in patient motion, and loss of coregistration of sequences with DWI. With multitransmit body coil modeling at 3T, studies have reported mixed results, with modeling reporting both reduced (27) and increased SAR deposition which is increased up to a factor of 13.4 times for focal deposition and 1.6 times for average whole-body scans (28).

Whole-body DWIBS is routinely viewed in inverted grayscale (i.e., black on white) because this format to view the raw b-value images directly in conjunction with conventional coregistered sequences. To detect such errors, it is beneficial to obtain sufficient background signal from the organ in question to be able to localize a lesion. Background signal is rapidly lost at high b-values (greater than 800 s/mm$^2$), with large patients, and with inhomogeneous RF maps. Increasing the number of averages to increase signal increases scan time. Near the diaphragm this can magnify errors. Therefore optimal b-value selection should be sought to provide the optimal target to background signal based on machine specific intrinsic resolution.

Misregistration is a common artifact that can occur most commonly at sites of maximum movement (i.e., near diaphragm, where with free-breathing techniques, the b-value maps are not obtained with the organ in question in the exact same position (Fig. 7). This results in ADC map noise, with the risk of loss of detection, or incorrect characterization of a lesion. This potential error can be minimized with diaphragm gating techniques, and stresses the importance of coregistered anatomic routine sequences acquired in conjunction with DWI.

At 3T, the benefit of increased SNR for DWI is offset by an increase in image distortion and artifacts. Field inhomogeneities are compounded, and dielectric effects, incomplete fat saturation and increased eddy currents result in increased DWI signal distortion. These effects can be mitigated by multitransmit RF shimming coils. Rosenkrantz et al (24) have demonstrated no significant difference in ADC values at 1.5T and 3T in matched patients with the same b-values and ADC calculation methods, however, the authors report significantly lower subjective image quality at 3T.

Use of conventional sequences with whole-body imaging at 3T is problematic due to specific absorption rate (SAR) heating effects which are proportional to the square of the static field and the flip angle. Thus the SAR limit is frequently attained at 3T (25). However, the higher SAR requires cooling pauses during scanning (26) which can result in patient motion, and loss of coregistration of sequences with DWI. With multitransmit body coil modeling at 3T, studies have reported mixed results, with modeling reporting both reduced (27) and increased SAR deposition which is increased up to a factor of 13.4 times for focal deposition and 1.6 times for average whole-body scans (28).

With whole-body DWI (DWIBS) the goal is to maximize lesion conspicuity. Unlike conventional morphologic sequences, where high inplane resolution is sought, with DWIBS, larger voxel size results in the ability to maximize signal to noise. Typically DWIBS is performed at 5-mm-thick slices. The three-dimensional (3D) data set can be reformatted into coronal, and sagittal planes which can be coregistered with conventional morphologic T1- and T2-based sequences. An example of a $b = 0$ coronal image 3 mm × 3 mm × 5 mm thick voxel is compared with a STIR image obtained with an inplane resolution of 1.6 × 1.6 × 5 mm thick voxel in Figure 8.

Whole-body DWIBS is routinely viewed in inverted grayscale (i.e., black on white) because this format...
has been found to improve the observer’s inherent retinal contrast resolution in experimental models (29). Similar to other functional nuclear medicine imaging techniques, the black on white versus white on black viewing setting is commonly based on physician preference.

Like all free-breathing techniques, whole-body DWIBS suffers near the diaphragm, particularly in the left lobe of the liver where cardiac pulsation results in signal loss as shown in Figure 9. This loss of signal can be minimized by cardiac and/or respiratory gating, and lower b-values. However, for whole-body DWIBS, quiet breathing is preferred to gating techniques to minimize scan time thus maximizing patient comfort. This free-breathing technique has been shown by Takahara et al to result in minimal signal loss (12).

The capability of combining conventional anatomic sequences with a functional technique (DWIBS) in one imaging tool shows promise to enable MRI with DWIBS to parallel the diagnostic advancements demonstrated by positron emission tomography/computed tomography (PET/CT). Combining MRI’s unique power of characterizing tissue based on water and fat content (i.e., T1 and T2 weighting) with DWI’s ability to assess tissue water motion and ADC provides a unique set of noninvasive imaging tools to both detect, and characterize lesions within tissue.

Clinical diffusion-weighted images are T2-weighted; thus, the native tissue being interrogated can elicit T2 shine through effects. Thus, to separate restricted diffusion tissue from T2 shine through effects, methods analogous to those applied to the brain can be used, namely comparison with standard T2 sequences, and with ADC maps/values. Normal tissue, which demonstrates restricted diffusion due to anisotropy, or tissue density include brain and spinal cord, spleen, lymph nodes, red marrow, ovaries, testes, and endometrium. Restricted tissue based on T2 shine through include normal gallbladder, salivary glands, prostate, and hemangiomas (30). Early hematomas in the body demonstrate similar findings to those shown in intracranial hemorrhages and appear restricted on DWI imaging because of both paramagnetic effects and restricted diffusion (31); thus, the importance of comparison with conventional sequences for appropriate tissue assessment is demonstrated in an example of an endometrioma (Fig. 10).

Bone marrow changes with age, disease, and post-chemoradiation is well demonstrated with PET/CT and skeletal scintigraphy, with DWIBS demonstrating analogous findings. Youth and marrow expansion conditions have increased red marrow within the tubular long bones, that shrinks with age to involve predominantly the axial skeleton. Hematogenous red marrow is known to have high cellularity giving restricted signal on DWI compared with yellow/fatty marrow, which has up to 70% less water (32). Thus, assessing marrow disease or infiltration from metastatic disease or multiple myeloma can be readily detected by DWIBS. Stecco et al (33) found DWIBS to have the same specificity as skeletal scintigraphy, with bone scintigraphy demonstrating limitations in the pelvis, coccyx, and sternum. DWIBS was found to show a higher specificity, but lower sensitivity with NaF PET/CT in patients with prostate bone metastasis (34). This lower sensitivity is likely due to the paucity of water within cortical bone; thus, cortical lesions may result in false negative findings on DWI.

**Figure 7. ADC misregistration due to breathing.** Upper left b-500, lower left b-50 demonstrates a lesion which is conspicuous from background tissue, with the lesion signal intensity dropping on the b-500 image. The relative signal change is typical for a simple cyst, as confirmed with hyperintense features on the axial T2 (lower middle) and coronal STIR sequences (right). The ADC map (upper center) shows no apparent hyperintense signal characteristic of a cyst due to the misregistration. Note the noise of the ADC map in the liver from breathing movement, which is not as apparent in the left kidney due to less movement.
DWI performed postgadolinium administration has been shown to have a similar appearance to DWI performed pregadolinium in the prostate, liver, spleen, pancreas, and kidney (35–37).

Whole-body imaging is commonly used as a survey for multisystem symptoms, and to determine metastatic spread or distant disease burden. This ability to perform a whole-body survey has been an advantage of scintigraphic nuclear medicine techniques, with colocalization from CT adding the benefit of lesion conspicuity to soft tissue background. DWIBS coregistered to morphologic MRI techniques provides similar lesion detection and localization capabilities without the radiation used by other techniques. MRI also has the advantage of improved soft tissue characterization. Through the combined interpretation of morphologic routine images and functional DWI, the sensitivity and specificity of whole-body MRI is maximized (38–40). Whole-body MRI with DWIBS is considered as an alternative tool to conventional whole-body methods for tumor staging and during follow-up in colorectal, myeloma, Hodgkins lymphoma, lung, and breast cancer patients with the difference between DWIBS and gadolinium contrast enhanced T1 MRI showing no statistical significance, with both techniques being comparable to FDG PET/CT (41). A meta-analysis of 1239 patients with whole-body MRI and FDG PET/CT comparing metastatic disease sensitivity found similar lesion detection capabilities between the two modalities (42).

**Figure 8.** Coronal whole-body images. The b-value image at b-0, shown as white on black, represents a fat saturated fluid sensitive sequence (a), however, the purpose of DWI as a functional technique is to maximize lesion conspicuity by maximizing signal to noise. Typically this is performed with 3 x 3 mm by 5 mm thick slices, as compared with the 1.6 mm x 1.6 mm inplane STIR sequence which demonstrates exquisite anatomic detail (b).

**Figure 9.** Axial b-500 image (a) demonstrates loss of signal within the left aspect of the liver from cardiac pulsation. The anatomy is not obscured on the axial T2 (b) image. This loss of signal is less problematic at low b-values and can be practically minimized by increasing the number of averages for DWI, or cardiac gating.

**Figure 10.** Whole-body coronal T1, DWI (b-500 shown as black on white), and STIR images demonstrating the conspicuity of the left adnexal subacute hemorrhage in an endometrioma due to the paramagnetic effects and restricted diffusion of blood degradation products.
To harness the maximum benefit of DWIBS and morphologic routine images, correlation with fat and water based high in plane resolution whole-body sequences such as T1 and STIR can be used. Five-millimeter-thick sections with DWIBS, T1, and STIR of the whole body can be acquired in approximately 40 min at 1.5T, with machine specific DWIBS protocols provided elsewhere (13).

Whole-body MRI conventional techniques coupled with DWIBS results in detection capabilities and characteristics for many oncologic conditions that are similar to that of FDG PET and bone scintigraphy, while adding the capability of allowing quantitative tumor volumes and response to therapy in new areas such as skeletal metastases, multiple myeloma, and lymphoma. These whole-body techniques by their inherent imaging volume allow improved repeatability and precision (43-46), which aid in assessment of response to therapy. The time and technique necessary to review a whole-body DWIBS with coregistered T1 and STIR is similar to that for a comparable PET/CT study. The overall approach to lesion quantification for diagnoses and follow-up is also analogous between standard uptake values (SUVs) of PET, and those of ADC measurements.

The vast majority of body DWI investigations have been performed at an individual organ specific level, which commonly include multiple varied, and often institution specific techniques. Thus, whole-body MRI techniques should typically not be used to supplant organ specific detailed MRI studies. To appropriately interpret DWIBS, as with all whole-body imaging modalities, a rigorous understanding of organ-based signal changes with disease processes is required.

**DWI BODY APPLICATIONS**

**Neck**

DWI applications to the head and neck are promising (47); however, the lower neck and shoulder region suffers from RF field inhomogeneity, which can induce frequent artifacts and edge of field errors. These can be overcome by imaging the region of interest in isocenter, and limiting the z axis field of view. Low b-values suffer from perfusion effects which may also include secretion effects from glandular tissues.

Thyroid nodule assessment for discrimination of benign versus malignant conditions has been performed in multiple studies. Mutlu et al (48) found using b-values of 0, 50, 400, and 1000, with comparison to the spinal cord at b-value of 1000 in 44 patients were able to achieve a specificity of 97% and accuracy of 98% compared with fine needle aspiration, with Nakahira et al (49) using an ADC cutoff of $1.6 \times 10^{-3}$ s/mm$^2$, demonstrating a specificity and accuracy of 83% and 88%, respectively.

DWI has been shown to improve primary lesion detection in squamous cell carcinoma and can aid in histologic grading and nodal spread compared with conventional CT, MRI, and PET (50-54), with preliminary studies incorporating DWI demonstrating favorable prognostic results for disease-free survival (55,56).

**Lung**

Discrimination of atelectasis from an associated pulmonary mass can be attained by visual inspection of the multiple b-value images, with the tumor mass demonstrating lower ADC than the adjacent collapsed lung (57).

A study by Regier et al (58) at 1.5T demonstrated that respiratory gated DWI compared with the gold standard of multidetector CT was 97% sensitive for detection of pulmonary nodules greater than 1 cm in diameter, and 86% sensitive for nodules measuring 6-9 mm in diameter. MRI and FDG PET are both susceptible to image blur, and resultant loss of resolution with free-breathing acquisition near the diaphragm when compared with the lung apex, where there is less lung movement with respiration.

In 2009, Ohba et al (59) performed a prospective study on solitary pulmonary nodules using both DWI and FDG PET, using surgical specimen histology as the reference standard. This study demonstrated similar sensitivity, with DWI being more specific than PET for nonsmall cell lung carcinoma, with Regier et al (60), demonstrating an inverse correlation with standard uptake values (SUV) and ADC values calculated from b-values of 0 and 500. Nodal assessment using DWI shows either similar results, or modest improvement compared with FDG PET (61-63).

**Breast**

Breast tissue demonstrates substantial heterogeneity, with women of childbearing age having predominantly glandular tissue, which limits mammographic sensitivity. Postmenopausal women have unique breast density ranging from almost entirely fat through which mammograms are well suited, to extremely dense breasts. DWI has been applied as a possible technique to aid in diagnosis of breast cancer detection. Many studies have been performed using combined dynamic contrast enhanced MRI in conjunction with DWI. These tests find variability in DWI sensitivity for detection of breast carcinoma from normal fibroglandular tissue, with ADC variations occurring across the menstrual cycle (64). Using b-values of 0 and 600, Partridge et al (65) have described a sensitivity of 96% and specificity of 55% for discrimination of benign versus malignant breast masses. The sensitivity and specificity is improved adding dynamic contrast enhancement, secondary to a vascular component within breast lesions (66,67). Intravoxel incoherent motion analysis on women with breast cancer has been performed by Sigmund et al (68), and these studies have described a biexponential shape of the diffusion curve in breast lesions. In women under 50, who most commonly have heterogeneously dense breast tissue, Kazama et al (69) demonstrate DWI using b-values of 0 and 800, combined with mammography results in significant improvement in malignancy sensitivity of 93% versus
mammography alone of 64% with insignificant specificity loss (85% versus 92%). Future studies examining perfusion, and diffusion ADC values in addition to mammography would be beneficial to ascertain the possibility for developing improved noninvasive lesion detection.

Genitourinary

DWI provides valuable functional information about lesions throughout the kidney, which can be seen to greater advantage than by conventional anatomic techniques. The cortical renal changes that occur in early childhood demonstrate increasing ADC with age, with the most rapid change occurring in the first year of life (70). The effect of pyelonephritis can readily be identified by DWI (71,72), without the use of contrast material (Fig. 11), whereas the findings by anatomic imaging and vascular enhancement can be subtle. The increase in viscosity of pyonephrosis can be demonstrated by a decrease in ADC values within the renal collecting system (73).

Chronic renal failure patients have been found to have significantly lower ADC values than patients with normal renal function (74). The kidneys have a bi-exponential curve, with both perfusion and diffusion components. With decreased renal perfusion from renal artery stenosis and acute ureteric obstruction, the cortical perfusion component (b-value < 100) has been shown to decrease (75). Separating acute renal failure from chronic renal failure, and correlation with glomerular filtration rate shows promise, with acute renal failure likely having a small decrease in ADC within the renal cortex, whereas chronic renal failure demonstrates a large decrease in ADC (74). In a small series of 4 patients within 19 days of renal transplant who demonstrated acute rejection, the marked decrease in perfusion measured by DWI correlated with creatinine clearance (76).

Investigation of renal cell carcinoma (RCC) discrimination from simple cysts and complex cysts has been undertaken by numerous studies, with nearly all incorporating b-values of zero into their linear monoexponential calculation of ADC values (77–80). Nonetheless, these studies are able to separate cystic fluid from solid mass by the marked difference in ADC values, with some authors using DWI to attempt to correlate subtype of RCC’s with histologic subtype (81,82). Zhang et al (83) found by retrospective review of the literature, that the lesions in the kidney were best described by an IVIM biexponential model, with further optimization techniques also being possible to maximize precision and accuracy (84). Incorporating both perfusion and diffusion for assessment of enhancing renal masses, Chandarana et al (85) found improved characterization of renal masses, with the tumor mass

Figure 11. Axial b-500 (a) readily demonstrates the increased signal from localized pyelonephritis, which cannot be identified on axial T2 (b) images. The subtle loss of arterial phase enhancement from pyelonephritis is shown in (c), with near complete loss of lesion conspicuity on delayed contrast enhanced images (d).
DWI perfusion components having good correlation with lesion vascularity, which may be beneficial in situations where contrast cannot be administered.

In patients with gross hematuria, DWI with b-values of 0 and 800 in conjunction with T2 images have been used to successfully identify bladder carcinoma with a sensitivity of 98% and a specificity of 92% (86). DWI in conjunction with T2 improves discrimination of superficial lesions from bladder invasion to 64% from 40% using T2 sequences alone (87), with several studies demonstrating ADC values correlating with histologic grading (88–90). With imaging for bladder tumors incorporating DWI, Takeuchi et al (91) were able to detect foci of restricted diffusion within the ureters and/or urethra that corresponded to synchronous tumors, or were from clot, with the signal intensity being secondary to the paramagnetic effect of blood detected by DWI. DWI has also been shown to separate postsurgical bladder wall inflammatory changes from bladder tumors (92).

Innumerable studies using DWI have been applied to the prostate gland, largely owing to the invasiveness, and high false negative rate of systematic ultrasound-guided biopsy. The central location of the gland within the body, and variably small size of the peripheral and transitional zones with age makes MRI assessment challenging. Applying a functional imaging technique in conjunction with routine morphological sequences has yielded improved tumor localization; however, the variability in imaging parameters, coil selection, and field strength without standardization makes comparison of results difficult. Due to the complexity of these problems, multiparametric assessment of the prostate gland has shown the most promise. These techniques include conventional anatomic sequences (T1 and T2), in addition to functional techniques of DWI, dynamic contrast enhanced MRI (dceMRI), which assesses perfusion, and H1 spectroscopy. A meta-analysis of 5892 prostate lesions has shown that DWI and T2 combined have a higher sensitivity and specificity (0.73,0.83) than dceMRI (0.58,0.82) alone (93). High b-values used in ADC calculations have shown the greatest promise in lesion localization (94,95); however, higher b-values suffer from loss of signal with an increase in noise (Fig. 4). DWI applied to the prostate can suffer greatly from inhomogeneous RF map which is magnified at higher b-values, and can limit evaluation of the prostate gland. This can be pronounced from gas in the rectum (Fig. 12), or from a poorly coupled endorectal coil. The latter of which also distorts the morphology of the prostate. Hoeks et al (96) for detection and tumor localization, suggest the minimal requirements for multiparametric imaging of the prostate is a combination of T1 and T2 sequences with either DWI or dceMRI using only a pelvic phased array coil, however, the addition of an endorectal coil is suggested for staging.

Assessment of perfusion in the prostate is commonly performed using intravenous gadolinium dceMRI; however, IVIM comparison studies (97) have shown promise in separating the perfusion from the diffusion components at low b-values (98). Higher order diffusion modeling (kurtosis) has shown further improvement in defining the non-Gaussian characteristics of the prostate gland (99), and ADC values have been shown to aid in tumor aggressiveness (100,101). Further improvement in tumor ADC utility within the peripheral gland has been shown in a small sample by accounting for the interpatient variability of ADC values in normal peripheral zone with a resultant nomogram developed to aid in risk assessment of tumor aggressiveness (102).

**Gynecologic Applications**

DWI has been found to be useful in detection of diffuse infiltrating endometriosis, by using the restricted diffusion from fibrotic tissue deposition (103) and paramagnetic effect from degrading hemoglobin to aid in lesion detection (Fig. 7). DWI with ADC values has been shown to separate endometrial cancer from...
normal endometrium and myometrium using 1.5T with a body array coil and b-values of 0 and 800 (104). DWI has been shown to separate cervical carcinoma from normal cervix at 1.5T with a body array coil and only two b-values of 0 and 800 (105). Using multiple b-value combinations (0, 150, 500, and 1000), Hoogendam (106) at 3T with a torso coil demonstrated all combinations of b-values are able to separate IB and IIA cervical carcinoma from normal cervical tissue. Tissue typing and histologic grading correlation with IVIM and multiple perfusion b-values has yet to be evaluated for cervical carcinoma; however, parametrial invasion and tumor extension is typically well characterized by conventional sequences.

Ovarian carcinoma is typically diagnosed noninvasively by conventional anatomic MRI techniques, and owing to the heterogeneity of ovarian mass tissue, the contribution of DWI is limited. However, recent studies have demonstrated incorporating dceMRI and DWI (b-value 0, 500, and 1000) yielded an improved accuracy of 95% in characterizing complex adnexal masses as benign or malignant. These functional techniques resulted in change in initial diagnosis ranging from 19 to 24% per reader compared with conventional sequences alone (107). Multiple b-values to evaluate the perfusion component in ovarian cancer has been assessed and demonstrates the capability to replace contrast enhancement in patients who are unable to have gadolinium (108,109). Additionally multiple b-value assessment has shown the difference in the perfusion component between ovarian primary, omental cake, and peritoneal carcinomatosis. Only changes in ADC of the ovarian mass occur with treatment. Other nonovarian malignant tissue diffusion characteristics remain unchanged (110). The stability of the peritoneal carcinomatosis and omental DWI findings are likely secondary to viscosity changes, rather than tumor vascularity changes being detected by DWI.

**Esophagus, Stomach, and Bowel**

A paucity of data is available in the literature regarding using DWI for assessment of the esophagus, stomach, and bowel. This may be due to the difficulty with susceptibility and motion from the gut. A single study reveals the detection capability of gastrointestinal stromal tumors (GIST) with DWI using oral water with the ability of the ADC (b-values of 0 and 1000) being able to differentiate good responders from treatment poor responders. In this study, initial pretreatment ADC values for poor responders was 1.24 versus 1.06 \( \times 10^{-3} \) s/mm\(^2\) for good responders, with the good responders demonstrating response to therapy by 1 week, characterized by an increase in ADC value to a mean of 1.60 \( \times 10^{-3} \) s/mm\(^2\) (111). DWI alone has been shown to aid in stomach mass lesion detection, with the possibility to discriminate between adenocarcinoma and lymphoma (112).

In small studies, DWI has been used in assessment of the esophagus with limited success, likely due to cardiac pulsation, and respiratory motion masking signal of the lower esophagus. In a trial of 24 patients, Sakurada et al (113) found a 49% primary tumor detection rate, with nodal group sensitivity of 39% and specificity of 93%. Aoyagi et al (114) found a correlation with restricted ADC values and stromal collagen in a small prospective esophagectomy trial of 17 patients.

Patients with inflammatory bowel disease are frequently assessed with imaging and colonoscopy. Most imaging is composed of CT scans; however, due to the young age of the population, there is rising concern about the long-term risks of CT radiation. Additionally, the invasiveness of colonoscopy, and the requirements for bowel preparation are onerous for patients. In a study comparing DWI (b-value 0, 600), gadolinium enhancement, bowel thickening, and colonoscopy in 35 patients with ulcerative colitis, and 61 with Crohn’s disease, Oussalah et al (115) found DWI to be as sensitive and specific for detecting segments of active inflammation as contrast enhanced MR enterography, without the need for oral or rectal preparation/contrast. Additionally these authors found DWI alone to be able to reliably detect inflammation in patients with ulcerative colitis. DWI (b-value 0, 50, 800) was found to be helpful in small bowel Crohn’s detection with a free-breathing technique, with ADC values being lower in affected segments (116). In a small study (n = 23) Kilickesmez et al (117) found DWI (b-value 0, 500, 1000) ADC values trending progressively lower from normal rectosigmoid colon, ulcerative colitis to lowest in adenocarcinoma, with overlap. ADC values in patients with ulcerative colitis of the rectosigmoid were also found to rise and normalize in patients responding to treatment (118).

Using b-values of 0 and 1000, Ichikawa et al (119) were able to assess colon primary carcinomas ranging in size from 2 to 7 cm, with a sensitivity of 91% and specificity of 100%, compared with postsurgical excision. Other studies using b-values of 50 and 800 have been used to assess rectal carcinoma ranging in size from 1.1 cm to 2.5 cm (120). The bowel, particularly the rectosigmoid colon, appears to be most sensitive to susceptibility artifact; however, by repositioning, this can be minimized (Fig. 12).

**Pancreas**

Evaluation of the pancreas with DWI continues to evolve. Examination of native pancreatic tissue demonstrates variation in ADC with location, age, and degree of fatty infiltration, with the tail having slightly lower ADC than the head and body (121,122). Variability of b-value selection, and thus ADC calculation has variable discrimination of normal tissue versus mass forming pancreatitis and pancreatic adenocarcinoma (123–125). These difficulties are compounded at 3T, where DWI is found to be of limited value (126), with slight improvement using ratios of lesion to background in assessing focal cystic pancreatic lesions (127). However, IVIM analysis at 1.5T yields differences in the perfusion component, with normal pancreas having the highest perfusion, which significantly decreases with mass forming pancreatitis, and further significantly decreases with adenocarcinoma.
Pancreatic adenocarcinoma can be discriminated from normal tissue with a reported sensitivity and specificity of 96% and 100%, respectively (129), versus 92% and 97% using free-breathing and ADC of b-values of 0 and 500 alone (130).

Pancreatic endocrine tumors are a rare variety of tumor, representing only 1 to 2% of pancreatic masses. Typically these are hypervascular on arterial phase contrast enhanced MRI; however, a small \( n = 18 \) retrospective study using fusion of T2 with b-value of 1000 on a 1.5T scanner showed a significant improvement in lesion detection compared with b-values alone (131). This finding is likely secondary to the loss of background tissue visible at higher b-values.

Liver

Many studies have been performed using DWI in the liver. These studies seek out diffusion characteristics to differentiate the liver based on fatty infiltration, cirrhosis, benign versus malignant liver primary tumor masses, hepatic metastases, and response to treatment. The variability of study design, equipment hardware, and b-value selection makes comparison of the individual studies difficult; however, trends are becoming apparent. Holzapfel et al (132) demonstrate that the conspicuity of lesions identified by DWI can be subcentimeter in size using respiratory gating at 1.5T with ADC values aiding in lesion characterization. Kim et al (133) demonstrate similar findings comparing small hepatocellular carcinomas (HCCs) detected on DWI alone versus rapid contrast washout, with other authors demonstrating DWI in conjunction with conventional sequences results in improved diagnostic sensitivity and reader confidence detecting small HCCs in cirrhotic livers (134). Park et al (135) suggest DWI alone is a reasonable alternative to contrast enhancement for lesions greater than 2 cm in size.

In general, the tissue composition (fluid versus semisolid/necrotic versus solid) results in progressive horizontal flattening of the diffusion curve, with the ADC values consequently dropping (Fig. 6b). Simple cysts, owing to their fluid nonvascular (and thus lack of perfusion) state have the highest ADC values, with no overlap between malignant primary liver lesions; however, overlap with necrotic metastases or treated lesions may occur. Hemangiomas have been shown to have ADC values near that of adjacent normal hepatic parenchyma (136,137), and choosing the cutoff \( 1.6 \times 10^{-3} \) s/mm\(^2\) proposed by Farikh et al (138) would separate hemangiomas from other liver lesions. The perfusion component of hepatic lesions was examined by Yamada et al (139) in an IVIM study, which revealed capillary flow in hemangiomas to contribute the highest perfusion followed by normal liver, metastases, then HCCs.

Fibronodular hyperplasia (FNH), and hepatic adenomas (HA) are easily detected by DWI; however, characterization of these mainly benign lesions by ADC value alone is limited secondary to overlap with malignant conditions (140). FNH lesions, while vascular, have yet to be examined by IVIM methods. Agnello et al (141), using b-values of 0, 150, and 600 found ADC values for FNH and HA to be significantly lower than adjacent normal liver, and they found by taking a ratio of lesion ADC to 15% below adjacent liver ADC resulted in appropriately characterizing 90% of FNH and 80% HA as benign.

DWI with IVIM have been used to assess liver fibrosis, and at 1.5T have demonstrated a decrease in ADC values ranging from 12 to 18% with liver fibrosis compared with normal controls (142,143). The IVIM studies demonstrate both a decrease in liver perfusion and true diffusion resulting in magnification of the drop in ADC. These findings correlate with drop in perfusion measured by dceMRI (143).

Malignant hepatic lesions such as HCC and metastases are readily visualized by DWI, with HCC demonstrating the lowest ADC values of all hepatic lesions (137), due to the low perfusion and restricted diffusion. Nasu et al (144) demonstrated no change in the low ADC values with degree of HCC differentiation.

After treatment of malignant disease in the liver, ADC values have been shown to change, typically before morphologic changes in tumor mass are demonstrated. Several authors (137,145) report their observational findings of increasing ADC with embolization and chemotherapy from cell lysis, with decreased ADC from antiangiogenic drugs, possibly due to impeded blood flow and reduction of extracellular volume.

CONCLUSION

DWI is a valuable functional imaging technique that can readily be applied to MRI of the whole body. Similar to all other combined anatomic and functional imaging techniques, DWI and conventional sequences demonstrate that the sum is greater than the individual parts, with DWI aiding in both lesion detection and characterization. Body tissue signal characteristics at various b-values is more complicated than simply obtaining a linear ADC value, with most tissues in the body having a perfusion component superimposed on top of the bulk tissue diffusion curve. Thus, calculating ADC values without extracting perfusion from the true diffusion component is rife for error, and this has led to great variability in quantifying tissue properties in the reported literature. IVIM studies applied to the body have demonstrated that using a cutoff b-value of 100 s/mm\(^2\) can reliably separate perfusion from bulk diffusion; with diffusion predominating at b-values greater than 100 s/mm\(^2\). Using two b-values at or above b-100 s/mm\(^2\) can then be used to more reliably calculate an ADC value. To minimize the chance of misregistration, and thus incorrect ADC map, it is ideal to choose b-values that maintain some background tissue signal. Typically b-values of 500 s/mm\(^2\) up to 800 s/mm\(^2\) demonstrate maximum separation between native healthy tissue and restricted (hypercellular or viscous) tissue, while maintaining background tissue visibility. The background tissue visibility is important for coregistration.
with other conventional sequences, and is especially important for free-breathing acquisitions. As no standards exist for measuring or calibrating machine specific intrinsic resolution and noise floor, it is important to choose b-values that yield adequate target to background ratios to confidently assess lesions. Despite the variability of reported b-values for ADC calculation, using DWI in body applications for lesion characterization in conjunction with T1- and T2-based sequences rivals or supersedes most other non-invasive imaging techniques, with low b-value (< 100 mm/s²) perfusion fraction demonstrating capabilities similar to perfusion dceMRI. Once standardized b-values are used to obtain both diffusion, and perfusion information from body imaging, DWI may limit the necessity for gadolinium contrast enhancement. DWI techniques coupled with anatomic conventional morphologic techniques will greatly aid in tissue characterization and reader confidence. This technique allows greater lesion conspicuity and characterization compared with other functional and anatomic imaging modalities, all with the benefit of no radiation.

REFERENCES

1. Eustace S, Tello R, DeCarvalho V, Carey J, Melhem E, Yucel EK. Whole body turbo STIR MRI in unknown primary tumor detection. J Magn Reson Imaging 1998;8:751–753.
2. Steinborn MM, Heuck AF, Zilting R, Bruegel M, Gauger L, Reiser MF. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 1999; 23:123–129.
3. Lauenstein TC, Freudenberg LS, Goede SC, et al. Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol 2002;12:2091–2099.
4. Kruger DG, Riederer SJ, Grimm RC, Rossman PJ. Continuously moving table data acquisition method for long FOV contrast-enhanced MRA and whole-body MRI. Magn Reson Med 2002;47:224–231.
5. Engelhardt K, Hollembach HP, Wohlfart K, von Imhoff E, Fellner FA. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004;14:99–105.
6. LeBihan D, Breton E. Image de diffusion in-vivo par resonance. C R Acad Sci (Paris) 1985;301:1109–1112.
7. Muller MF, Feldman RR. Echo planar imaging of the abdomen. Top Magn Reson Imaging 1995;7:112–119.
8. Wang Y. Description of parallel imaging in MRI using multiple coils. Magn Reson Med 2000;44:495–499.
9. Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET/CT. Eur Radiol 2007;17:939–949.
10. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient. J Chem Phys 1965;42:288–293.
11. Einstein A. On the movement of small particles suspended in stationary liquids required by the kinetic theory of heat. Ann Der Physik 1905;17:549–560.
12. Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004;22:275–282.
13. Koh D-M, Blackledge M, Padhani AR, et al. Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 2012;199:252–262.
14. LeBihan D, Breton E, Lallemand D, Gremier P, Cabanas E, Laval-Jeantet M. MR Imaging of incoherent motion: application to diffusion and perfusion in neurologic disorders. Radiology 1986;161:401–407.
15. Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. AJR Am J Roentgenol 2011;196:1351–1361.
16. LeBihan D, Turner R. The capillary network: a link between IVIM and classical perfusion. Magn Reson Med 1992;27:171–178.
17. Lemke A, Laun FB, Simon D, Stieljes B, Schad LR. An in vivo verification of the intravoxel incoherent motion effect in diffusion-weighted imaging of the abdomen. Magn Reson Med 2010;64:1580–1585.
18. Uto T, Takehara Y, Nakamura Y, et al. Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 2009;252:247–254.
19. Baysal T, Bulut T, Gokirmak M, et al. Diffusion-weighted MR imaging of pleural fluid: differentiation of transudative vs exudative pleural effusions. Eur Radiol 2004;14:890–896.
20. Inan N, Arslan A, Akansel G, et al. Diffusion-weighted MRI in the characterization of pleural effusions. Diag Interv Radiol 2009;15:13–18.
21. Eickkurt M, Doganay S, Kantarci M, et al. Comparison of peripheral tumor imaging using conventional MR imaging and diffusion-weighted MR imaging with different b values. Eur J Radiol 2011;80:224–228.
22. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peripheral tumors: comparison with conventional MRI and surgical and histopathologic findings—a feasibility study. AJR Am J Roentgenol 2009;193:461–470.
23. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009;11:102–125.
24. Rosenkrantz AB, Oei M, Babar JS, Niver BE, Taouli B. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 2011;33:128–135.
25. Ziegler-Bergner G, Ingoldstaedter L. ICNIRP Statement on the guidelines for limiting exposure to time-varying electric, magnetic and electromagnetic fields [up to 300GHz]. Health Phys 2009;97:257–258.
26. International Commission on Non-Ionizing Radiation Protection. Guidelines on limiting exposure to static magnetic fields. Health Phys 2009;66:504–513.
27. Harvey PR, Zhai Z, Morich M, et al. SAR behavior during whole-body multi transmit RF shimming at 3.0T. In: Proceedings of the 17th Annual Meeting of ISMRM, Honolulu, 2009. (abstract 4786).
28. Neufeld E, Gosselin M-C, Murbach M, et al. Analysis of the local worst-case SAR exposure caused by an MRI multi-transmit body coil in anatomical models of the human body. Phys Med Biol 2011;56:4649–4659.
29. Enroth-Cugell C, Shapley RM. Flux, not retinal illumination, is what cat retinal ganglion cells really care about. J Physiol 1973; 233:311–326.
30. Padhani AR, Koh DM, Collins DJ. Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 2011;261:700–718.
31. Atlas SW, DuBois P, Singer MB, Lu D. Diffusion measurements in intracranial hematomas: implications for MR imaging of acute stroke. AJNR Am J Neuroradiol 2000;21:1190–1194.
32. Goodsell MM, Hoover P, Veldee MS, Hsieh SL. The composition of bone marrow for a dual-energy quantitative computed tomography technique. A cadaver and computer simulation study. Invest Radiol 1994;29:695–704.
33. Stecco A, Lombardi M, Leva L, et al. Diagnostic accuracy and agreement between whole-body diffusion MRI and bone scintigraphy in detecting bone metastases. Radiol Med 2013;118:465–475.
34. Mosavi F, Johansson S, Sandberg DT, Turesson I, Sorensen J, Ahlstrom H. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol 2012; 199:1114–1120.
35. Liu X, Zhou L, Peng W, Qian M. Effect of intravenous gadolinium-DTPA on diffusion-weighted imaging for prostate lesions and normal tissue at 3.0-Tesla magnetic resonance imaging. Acta Radiol 2011;52:575–580.
36. Wang CL, Chea YW, Boll DT, et al. Effect of gadolinium chelate contrast agents on diffusion weighted MR imaging of the liver, spleen, pancreas and kidney at 3 T. Eur J Radiol 2011;80:e1–e7.

37. Kinner S, Umuthu L, Blex S, et al. Diffusion weighted MR imaging in patients with HCC and liver cirrhosis after administration of different gadolinium contrast agents: is it still reliable? Eur J Radiol 2012;81:e625–e628.

38. Kwee TC, van Ufford HM, Beek FJ, et al. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography. Invest Radiol 2009;44:683–690.

39. Gu J, Chan T, Zhang J, Luong NY, Kwong YL, Khong PL. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 2011;197:W384–W391.

40. Fischer MA, Nanz D, Hany T, et al. Diagnostic accuracy of whole-body MRI/DWI image fusion for detection of malignant tumours: a comparison with PET-CT. Eur Radiol 2011;21:246–255.

41. Manenti G, Cicco C, Squillacci E, et al. Role of combined DWIBS/3D-CE-T1w whole-body MRI in tumor staging: comparison with PET-CT. Eur J Radiol 2012;81:1917–1925.

42. Xu GZ, Li CY, Zhao L, He ZY. Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis. Ann Oncol 2013;24:98–101.

43. Sommer G, Klarhofer M, Lenz C, et al. Signal characteristics of focal bone marrow lesions in patients with multiple myeloma using whole body T1w-TSE, T2w-STIR and diffusion-weighted imaging with background suppression. Eur Radiol 2011;21:857–860.

44. Schmidt GP, Reiser MF, Baur-Melnyk A. Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 2009;70:393–400.

45. Marzolini M, Wong WL, Ardesha K, Padhani A, D’Sa S. Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma. Br J Hematol 2012;156:557.

46. Padhani AR, Gogbashian A. Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer imaging 2011;11 Spec No:S129–S145.

47. Thoery HC, De Keizer F, King AD. Diffusion-weighted MR imaging in the head and neck. Radiology 2012;263:19–32.

48. Mutlu H, Sivrioglu AK, Sonmez G, et al. Role of apparent diffusion coefficient values and diffusion-weighted magnetic resonance imaging in differentiation between benign and malignant thyroid nodules. Clin Imaging 2012;36:1–7.

49. Nakamura M, Saito N, Murata S-I, et al. Quantitative diffusion-weighted magnetic resonance imaging in differentiation of postobstructive consolidation from central lung carcinoma. Magn Reson Imaging 2009;27:1447–1454.

50. Regier M, Schwarz D, Henes FO, et al. Diffusion-weighted MR imaging for the detection of pulmonary nodules at 1.5 Tesla: intraindividual comparison with multidetector computed tomography. Invest Radiol 2011;46:110–116.

51. Ohya Y, Nomori H, Mori T, et al. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg 2009;138:439–445.

52. Thoery HC, De Keizer F, Oven RH, Peeters RR. Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience. Radiology 2005;235:917–919.

53. Berrak S, Chawla S, Kim S, et al. Diffusion-weighted imaging in predicting progression free survival in patients with squamous cell carcinomas of the head and neck treated with induction chemotherapy. Acad Radiol 2011;18:1225–1232.

54. Thoery HC, De Keizer F, Oven RH, Peeters RR. Diffusion-weighted MR imaging of native and transplanted kidneys. Radiology 2011;259:25–38.
Whole Body MRI With Diffusion

76. Eisenberger U, Thoery HC, Binser T, et al. Evaluation of renal allograft function early after transplantation with diffusion-weighted MR imaging. Eur Radiol 2010;20:1374–1383.

77. Cova M, Squillaci E, Staicul F, et al. Diffusion-weighted MRI in the evaluation of renal lesions: preliminary results. Br J Radiol 2004;77:851–857.

78. Zhang J, Tehrani YM, Wang L, Ishii NM, Schwarz LH, Hricak H. Renal masses: characterization with diffusion-weighted MR imaging—a preliminary experience. Radiology 2008;247:458–464.

79. Sandrasegaran K, Sundaram CP, Ramaswamy R, et al. Usefulness of diffusion-weighted imaging in the evaluation of renal masses. AJR Am J Roentgenol 2010 Feb;194:438–45.

80. Kim S, Jain M, Harris AB, et al. T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology 2009;251:796–807.

81. Wang H, Cheng L, Zhang X, et al. Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology 2010;257:135–143.

82. Goyal A, Sharma R, Bhalla AS, et al. Diffusion-weighted MRI in renal cell carcinoma: a surrogate marker for predicting nuclear grade and histological subtype. Acta Radiol 2012;53:349–358.

83. Zhang JL, Sigmund EE, Chandarana H, et al. Variability of renal apparent diffusion coefficients: limitations of the monoeponential model for diffusion quantification. Radiology 2010;254:783–792.

84. Zhang JL, Sigmund EE, Rusinek H, et al. Optimization of b-value sampling for diffusion-weighted imaging of the kidney. Magn Reson Med 2012;67:89–97.

85. Chandarana H, Lee VS, Hecht E, Taouli B, Sigmund EE. Comparison of biexponential and monoeponential model of diffusion-weighted imaging in evaluation of renal lesions: preliminary experience. Invest Radiol 2011;46:285–291.

86. Abou-El-Gharmi ME, El-Assmy A, Refaie HF, El-Diasty T. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology 2009;251:415–421.

87. El-Assmy A, Abou-El-Gharmi ME, Mosbah A, et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009;19:1575–1581.

88. Takeuchi M, Sasaki S, Ito M, et al. Urinary bladder cancer: diffusion-weighted MR imaging—accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009;251:112–121.

89. Avcu S, Koseoglu MN, Ceylan K, Bulut MD, Dhubalatand M, Unal O. The value of diffusion-weighted MRI in the diagnosis of malignant benign urinary bladder lesions. Br J Radiol 2011;84:875–882.

90. Kobayashi S, Koga F, Yoshida S, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011;21:2178–2186.

91. Takeuchi M, Suzuki T, Sasaki S, et al. Clinicopathologic significance of high signal intensity on diffusion-weighted MR imaging in the ureter, urethra, prostate and bone of patients with bladder cancer. Acad Radiol 2012;19:827–833.

92. El-Assmy A, Abou-El-Gharmi ME, Refaie HF, Mosbah A, El-Diasty T. Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int 2012;110:e622–e627.

93. Tan CH, Wei W, Johnson V, Kundra V. Diffusion-weighted MRI in the detection of prostate cancer: meta-analysis. AJR Am J Roentgenol 2012;199:822–829.

94. Thorner G, Otto J, Reiss-Zimmermann M, et al. Diagnostic value of ADC in patients with prostate cancer: influence of the choice of b values. Eur Radiol 2012;22:1820–1828.

95. Rosenkrantz AB, Mannelli L, Kong X, et al. Prostate cancer: utility of fusion of T2-weighted and high b-value diffusion-weighted images for peripheral zone tumor detection and localization. J Magn Reson Imaging 2011;34:95–100.

96. Hoeks CMA, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011;261:46–66.

97. París Y, Turvey J, Bernardo M, et al. Intravoxel incoherent motion MR imaging for prostate cancer: an evaluation of perfusion fraction and diffusion coefficient derived from different b-value combinations. Magn Reson Med 2013;69:553–562.

98. Mazzaheri Y, Vargas HA, Akin O, Goldman DA, Hricak H. Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: evaluation of a revised monoeponential model within a clinical setting. J Magn Reson Imaging 2012;35:660–668.

99. Rosenkrantz AB, Sigmund EE, Johnson G, et al. Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model and its detection and assessment of aggressiveness of peripheral zone cancer. Radiology 2012;264:126–135.

100. Oto A, Yang C, Kayhan A, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. J Magn Reson Imaging 2010;31:1382–1390.

101. Nagarajan R, Margolis D, Raman S, et al. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol 2012;2012:374805.

102. Lijtens GJS, Hambrock T, Hulsbergen-van de Kaa C, Barentsz JO, Huisman HJ. Intertumor variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology 2012;265:260–266.

103. Busard MPH, Mijatovic V, van Kuijk C, Pieters-van den Bos IC, Hompes PGA, van Waesberge JHTM. Magnetic resonance imaging in the evaluation of (deep infiltrating) endometriosis: the value of diffusion-weighted imaging. J Magn Reson Imaging 2010;32:1003–1009.

104. Inada Y, Matsuiki M, Nakai G, et al. Body diffusion-weighted MR imaging of uterine endometrial cancer: is it helpful in the detection of cancer in nonenhanced MR imaging? Eur J Radiol 2009;70:122–127.

105. Chen J, Zhang Y, Liang B, Yang Z. The utility of diffusion-weighted MR imaging in cervical cancer. Eur J Radiol 2010;74:e101–e106.

106. Hoogendam JP, Klerkx WM, de Kort GAP, et al. The influence of the b-value combination on apparent diffusion coefficient based differentiation between malignant and benign tissue in cervical cancer. J Magn Reson Imaging 2010;32:376–382.

107. Thomassin-Naggara I, Toussaint I, Perrot N, et al. Characterization of complex adenomal masses: value of adding perfusion- and diffusion-weighted MR imaging to conventional MR imaging. Radiology 2011;258:793–803.

108. Thoery HC, Forstner R, De Keyzer F. Genitourinary applications of diffusion-weighted MR imaging in the pelvis. Radiology 2012;263:326–342.

109. Sala E, Priest AN, Kataoka M, et al. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3 Tesla: technical development. Eur Radiol 2010;20:491–496.

110. Sala E, Kataoka MY, Priest AN, et al. Advanced ovarian cancer: multiparametric MR imaging demonstrates response-metastasis-specific effects. Radiology 2012;263:149–159.

111. Tang L, Zhang X-P, Sun Y-S, et al. Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients. Radiology 2011;258:729–738.

112. Avcu S, Arslan H, Unal O, Kotan C, Izmirli M. The role of diffusion-weighted MR imaging and ADC values in the diagnosis of gastric tumors. JBR-BTR 2012;95:1–5.

113. Sakurada A, Takahara T, Kwee TC, et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Eur Radiol 2009;19:1461–1469.

114. Aoyagi T, Shuto K, Okazumi S, et al. Apparent diffusion coefficient correlation with oesophageal tumour stroma and angiogenesis. Eur Radiol 2012;22:1172–1177.

115. Oussalah A, Laurenti V, Bruot O, et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 2013;62:1056–1065.

116. Kiyru S, Sodanuki K, Takao H, et al. Free-breathing diffusion-weighted imaging for the assessment of inflammatory activity in Crohn’s disease. J Magn Reson Imaging 2009;29:880–886.

117. Kılıckesmez O, Atilla S, Bayramoglu S, Gurmen N. Diffusion-weighted imaging of the rectosigmoid colon. J Comput Assist Tomogr 2009;33:863–866.

118. Kılıckesmez O, Soylu A, Yasar N, et al. Is quantitative diffusion-weighted MRI a reliable method in the assessment of the inflammatory activity in ulcerative colitis? Diag Interv Radiol 2010;16:293–298.
119. Ichikawa T, Erturk SM, Motosugi U, et al. High-B-value diffusion-weighted MRI in colorectal cancer. AJR Am J Roentgenol 2006;187:181–184.
120. Hosonuma T, Tozaki M, Ichiba N, et al. Clinical usefulness of diffusion-weighted imaging using low and high b-values to detect rectal cancer. Magn Reson Med 2006;5:173–177.
121. Yoshikawa T, Kawaiitsu H, Mitchell DG, et al. ADC measurement of abdominal organs and lesions using parallel imaging technique. AJR Am J Roentgenol 2006;187:1521–1530.
122. Schoennagel BP, Habermann CR, Roesch M, et al. Diffusion-weighted imaging of the healthy pancreas: apparent diffusion coefficient values of the normal head, body, and tail calculated from different sets of b-values. J Magn Reson Imaging 2011;34:861–865.
123. Wiggermann P, Grützmann R, Weissenoek A, Kamusella P, Dittert D-D, Stroszczyński C. Apparent diffusion coefficient measurements of the pancreas, pancreas carcinoma, and mass-forming focal pancreatitis. Acta Radiol 2012;53:135–139.
124. Kamisawa T, Takuma K, Anjiki H, et al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am J Gastroenterol 2010;105:1870–1875.
125. Ichikawa T, Erturk SM, Motosugi U, et al. High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results. AJR Am J Roentgenol 2007;188:409–414.
126. Fukukura Y, Takumi K, Kamimura K, et al. Pancreatic adenocarcinoma: variability of diffusion-weighted MR imaging findings. Radiology 2012;263:732–740.
127. Mottola JC, Sahni VA, Erturk SM, Swanson R, Banks PA, Mortele KJ. Diffusion-weighted MRI of focal cystic pancreatic lesions at 3.0-Tesla: preliminary results. Abdom Imaging 2012;37:110–117.
128. Klauss M, Lemke A, Grünberg K, et al. Intravoxel incoherent motion MRI for the differentiation between mass forming chronic pancreatitis and pancreatic carcinoma. Invest Radiol 2011;46:57–63.
129. Lemke A, Laun FB, Klauss M, et al. Differentiation of pancreas carcinoma from healthy pancreatic tissue using multiple b-values: comparison of apparent diffusion coefficient and intravoxel incoherent motion derived parameters. Invest Radiol 2009;44:769–775.
130. Kartalis N, Lindholm TL, Aspelin P, Pernert J, Albiin N. Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol 2009;19:1981–1990.
131. Brenner R, Metens T, Bali M, Denetper C, Mats C. Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. Eur J Radiol 2012;81:e746–e749.
132. Holzapfel K, Bruegel M, Eber M, et al. Characterization of small (<10 mm) focal liver lesions: value of respiratory-triggered echo-planar diffusion-weighted MR imaging. Eur J Radiol 2010;76:89–95.
133. Kim DJ, Yu J-S, Kim JH, Chung J-J, Kim KW. Small hypervascular hepatocellular carcinomas: value of diffusion-weighted imaging compared with "washout" appearance on dynamic MRI. Br J Radiol 2012;85:e879–e886.
134. Le Moigne F, Durieux M, Bance B, et al. Impact of diffusion-weighted MR imaging on the characterization of small hepatocellular carcinoma in the cirrhotic liver. Magn Reson Imaging 2012;30:656–665.
135. Park M-S, Kim S, Patel J, et al. Hepatocellular carcinoma: detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology 2012;56:140–148.
136. Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008;18:477–485.
137. Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic applications of diffusion-weighted MRI in the body. J Magn Reson Imaging 2012;35:257–279.
138. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008;246:812–822.
139. Yamada I, Aung W, Himeno Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999;210:617–623.
140. Donati F, Boraschi P, Gigan R, Saleni S, Falaschi F, Bartolozzi C. Focal nodular hyperplasia of the liver: diffusion and perfusion MRI characteristics. Magn Reson Imaging 2013;1:10–16.
141. Aghello F, Ronot M, Valla DC, Sinkus R, Van Beers BE, Vilgrain V. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis. Radiology 2012;262:511–519.
142. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging–pilot study. Radiology 2008;249:891–899.
143. Patel J, Sigmund EA, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010;31:589–600.
144. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009;193:438–444.
145. Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 2012;35:745–763.